NCT01473316已完成1 期
An Open-Label, Fixed-Sequence, 2-Period Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 主要终点
- Pharmacokinetics: maximum observed plasma concentration
研究概览
简要总结
This will be an open-label, fixed-sequence, single-center, 2 period study. The study is designed to determine the effect of ketoconazole on the pharmacokinetics of GDC-0980.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy postmenopausal and/or surgically sterile adult nonsmoking female subject between 18 and 65 years of age, inclusive, with a body mass index of 18 to 32 kg/m2, inclusive
- •Medically healthy as determined by the absence of clinically significant findings in the physical examination, medical history, vital sign measurements, clinical laboratory tests, or 12 lead electrocardiograms (ECGs) as determined by the investigator
- •Female subject of nonchildbearing potential
排除标准
- •History or clinical manifestations of significant metabolic (including type 1 and 2 diabetes), hepatic, renal, hematological (including hypercholesterolemia and triglyceridemia), pulmonary, cardiovascular, endocrine, gastrointestinal (including gastric or duodenal ulcers), urological, neurological, or psychiatric disorders, or cancer
- •History of inflammatory arthritis
- •History of symptomatic hypotension
- •History of severe physical injury, direct impact trauma, or neurological trauma within 6 months before Day 1 of Period 1
- •History of seizure disorders
- •History of bipolar or major depressive disorder
- •History of stomach or intestinal surgery or resection that could potentially alter absorption and/or excretion of orally administered drugs, with the exception of appendectomy, hernia repair, and cholecystectomy, which are allowed
- •History of active liver disease, including hepatitis or cirrhosis
- •History or presence of an abnormal ECG
- •History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
- •Abnormality on the chest x-ray at Screening determined to be clinically significant by the investigator and medical monitor
- •History of alcoholism, drug abuse, or drug addiction
- •Used any nicotine-containing or nicotine-replacement products within 6 months before Day 1 of Period 1
- •Participated in any other investigational drug study in which receipt of an investigational study drug occurred within 1 month or 5 half-lives before Day 1 of Period 1
- •Used any prescription medications/products including monoamine oxidase inhibitors, thioridazine, pimozide, or antidepressants within 1 month (2 weeks for antibiotics) before Day 1 of Period 1, with the exception of hormone replacement therapy or 2 weeks' use of narcotics for pain, unless deemed acceptable by the investigator
- •Used medications capable of inhibiting hepatic enzymes within 1 month or 5 half-lives before Day 1 of Period 1
- •Received any vaccination or immunization within 1 month before Day 1 of Period 1
- •Used proton pump inhibitors or histamine H2 receptor antagonists within 1 month before Day 1 of Period 1
- •Known hypersensitivity to ketoconazole, or other azole antifungals
- •Used any over-the-counter, nonprescription preparations within 7 days before Day 1 of Period 1, unless deemed acceptable by the investigator
- •Used alcohol-containing, grapefruit-containing, or caffeine containing foods or beverages within 72 hours before Day 1 of Period 1, unless deemed acceptable by the investigator
- •Poor peripheral venous access
- •Donated blood within 2 weeks or plasma within 1 week before Day 1 of Period 1
- •Received blood products within 2 months before Day 1 of Period 1
- •Positive urine drug or alcohol screen
- •Positive screen for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus types 1 and 2
- •Diagnosed with a vitamin B12 deficiency
- •Any acute or chronic condition that, in the opinion of the investigator, would limit the subject's ability to complete or participate in this clinical study
研究组 & 干预措施
A
Experimental
干预措施: GDC-0980 (Drug)
A
Experimental
干预措施: Ketoconazole (Drug)
结局指标
主要结局
Pharmacokinetics: maximum observed plasma concentration
时间窗: Up to approximately 10 days
Pharmacokinetics: time to reach maximum observed plasma concentration
时间窗: Up to approximately 10 days
次要结局
- Adverse events(Up to approximately 40 days)
- Vital sign measurements (sitting systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature)(Up to approximately 8 days)
- Clinical laboratory test results (hematology and serum chemistry)(Up to approximately 10 days)
研究者
相似试验
已完成
1 期
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the BodySolid TumorsNCT04187456AstraZeneca14
已完成
1 期
Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961Healthy VolunteerNCT04495140Pfizer6
撤回
1 期
A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.Healthy VolunteerNCT02019290Hoffmann-La Roche
已完成
1 期
A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy SubjectsHealthy VolunteerNCT01967979Hoffmann-La Roche28
已完成
1 期
A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.Prostatic HyperplasiaNCT01254071GlaxoSmithKline86